SynthesisMedicine2025
Efficacy and outcomes of dapagliflozin in diabetic nephropathy: A systematic review and meta-analysis.
Synthesis in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pilot study on the effects of dapagliflozin on echocardiographic parameters in dogs with symptomatic myxomatous mitral valve disease.Veterinary and animal science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic nephropathy is one of the most prevalent consequences of diabetes and is associated with increased morbidity and mortality in diabetic patients. The pathogenesis of Diabetic Nephropathy is very complex and is still not fully understood, resulting in poor therapeutic outcomes. Dapagliflozin is thought to be associated with decreased progression of diabetic nephropathy. However, fewer trials have been conducted for the role of dapagliflozin in human patients with diabetic nephropathy. This is the first systematic review and meta-analysis where we aim to generate appropriate evidence regarding the safety and efficacy of dapagliflozin in diabetic nephropathy.
methodsWe searched the databases like PubMed, MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) and Embase for studies published from inception to November 2023. Bias assessment was done using risk of bias tool for randomized controlled trial (RCT) and Newcastle-Ottawa scale for non-randomized studies. Synthesis of the data was done using RevMan 5.4 software. Efficacy was assessed in terms of lowering HbA1c level, serum creatinine, and urine albumin-to-creatinine ratio. Statistical heterogeneity was measured by using the I squared test and the results were reported using forest plots.
resultsTwo studies were selected, 1 RCT and 1 comparative study including 296 patients. The dapagliflozin-treated group showed significant improvements in lowering serum creatinine [Standardized mean difference (SMD): -0.56 (-1.08, -0.04), P < .00001] and HbA1c [SMD: -0.84 (-1.07, -0.61), P = .03] when compared to the control group. But there was no discernible change in urine albumin-to-creatinine ratio [SMD: -1.45 (-3.33, 0.42), P = .13] after dapagliflozin therapy. Hypoglycemia [risk ratio: 0.26 (0.08-0.82), P = .02] was considerably lower in the dapagliflozin treatment group than in the control group in terms of safety.
conclusionThis meta-analysis showed that dapagliflozin was more effective in treating diabetic nephropathy while having fewer side effects. Our results support to the endeavor of conducting bigger, multicentre RCTs that assess dapagliflozin's efficacy and delineate its unfavorable risk profile.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.